A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843 ↗

Phase 2 Completed 19 enrolled Memorial Sloan Kettering Cancer Center Amgen · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Timeline

Start: 2016-06-21
Primary completion: 2024-02-22
Completion: 2024-02-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talimogene Laherparepvec	Other / unclassified	1e+08 unknown	Other

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Summary

Timeline

Drugs

Indications